Serina is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina’s POZ Platform™ delivery technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (“PEG”) and other biocompatible polymers. Serina's POZ Platform™ partners are at the forefront in advancing LNP delivery technology to develop novel RNA therapeutics. Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.